<\/p>\n
Salveen Richter<\/strong><\/span> Raj, could you start by giving us a brief overview of where your portfolio stands today, your updated strategic focus on the cardiovascular and autoimmune franchise? And how you’re thinking about technologies as you bring in new modalities, including [ siRNA ] and in vivo CAR-T?<\/p>\n<\/p><\/div>\n Raju Prasad<\/strong><\/span> Yes, absolutely. And thank you for having us at the Goldman conference once again, and it’s great to be here. CRISPR is now over 12 years old, we’re entering sort of our teen years as a company. And with that, in addition to CASGEVY, which is our approved product with commercial partner in Vertex, which I’m sure we’ll talk about; we really have been focusing on the pipeline and identifying what our next second, third, fourth programs are. <\/p>\n And you mentioned cardiovascular and autoimmune disease and we’re looking at those therapeutic areas, specifically in how we build sort of the clinical development apparatus of the company as well. And I think with regards to how this pipeline is going to shape up and how it will frame the next phase of growth for CRISPR as a company, is that in the back half of this year, we’ll have 5 clinical trial readouts across 3 programs. <\/p>\n We have CTX611, which is an siRNA program with a partner, Sirius Therapeutics, and<\/p>\n<\/p><\/div>\n #CRISPR #Therapeutics #CRSP #Presents #Goldman #Sachs #47th #Annual #Global #Healthcare #Conference #Transcript<\/p>\n","protected":false},"excerpt":{"rendered":" Salveen RichterGoldman Sachs Group, Inc., Research Division Raj, could you start by giving us a brief overview of where your portfolio stands today, your updated strategic focus on the cardiovascular… <\/p>\n","protected":false},"author":1,"featured_media":5445,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[242],"tags":[8730,1106,1726,8920,8921,485,1360,4517,4894,1361,2847,535],"class_list":["post-6488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editors-pick","tag-47th","tag-annual","tag-conference","tag-crispr","tag-crsp","tag-global","tag-goldman","tag-healthcare","tag-presents","tag-sachs","tag-therapeutics","tag-transcript"],"_links":{"self":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts\/6488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6488"}],"version-history":[{"count":0,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts\/6488\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/media\/5445"}],"wp:attachment":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Goldman Sachs Group, Inc., Research Division<\/i><\/span><\/p>\n
Chief Financial Officer<\/i><\/span><\/p>\n